4%, 95% CI: 25.5,98.2), but not during the second year (−54.7%, 95% CI: −1752.7,82.3); only 5 RVGE occurred during the second year. For every 100 person-years of follow-up for the entire study period, 1.8 cases of severe RVGE were prevented by PRV; during the first year of life, 3.3 cases of severe RVGE were prevented for 100 person-years.
For this analysis of clinic based-data, PRV did not have significant efficacy against all or severe gastroenteritis of any cause (Table 2). Although there was a slight increase in severe non-rotavirus gastroenteritis among the PRV group, this difference was not significant during the entire follow-up period (VE −15.1%, 95% CI: −55.0,59.2). In the intention-to-treat analysis of the entire study period, there were 6 cases of severe RVGE in PRV recipients and 15 cases in placebo recipients, Talazoparib yielding an efficacy of 59.1% (95% CI: 11.5,87.0). In the first year of life in the intention-to-treat analysis, there were 3 RVGE cases among PRV recipients and 13 among placebo recipients, yielding an efficacy against severe RVGE of 76.4% (95% CI: 14.1,95.7). Among HIV-infected children identified at enrollment who were evaluable during the follow-up period, there was one case of severe RVGE among PRV recipients and no cases among placebo recipients (IRR undefined,
Table 3). Selleckchem Dinaciclib There were more cases of severe gastroenteritis due to any cause among HIV-infected PRV recipients than among HIV-infected placebo recipients,
but this did not meet statistical significance (5/21 vs. 1/17 respectively, IRR 7.6, 95% CI: 0.85,361). None of the 8 infants who developed HIV-infection after enrollment during the HIV-testing at 6, 9 and 12 weeks, presumably though breast-feeding, experienced RVGE after they tested HIV-positive. One child, a PRV recipient, developed severe RVGE at 8 months of age, before having a newly positive PCR test for HIV at 12 months. Phosphoprotein phosphatase Among almost 15,000 home visits, a total of 3143 episodes of gastroenteritis in the prior 2 weeks were reported, of which 199 (6.3%) were classified with severe dehydration and 488 (15.5%) with moderate dehydration (Table 4). The vaccine efficacy against gastroenteritis with severe dehydration during the entire study period was 29.7% (95% CI: 2.5,49.3); efficacy during the first year was 34.4% (95% CI: 5.3,54.6) and during the second year was 18.3% (95% CI: −44.9,54.0). During the entire follow-up period, 12 cases of gastroenteritis with severe dehydration per 100 person-years were prevented by PRV (95% CI: 3,22), and 19 cases per 100 person-years in the first year (95% CI: 4,34). Using the modified Clark scoring system, although fewer gastroenteritis cases were classified as severe than when using IMCI criteria, PRV showed a similar point estimate for protective efficacy against severe gastroenteritis in the first year, although not statistically significant (34.8%, 95% CI: −19.6,64.4).
Related posts: